Central Serous Chorioretinopathy (CSC)

2

Review clinical trials related to Central Serous Chorioretinopathy (CSC). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial

Dysregulation of the Angiopoietin-2 (Ang-2)/Tyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous chorioretinopathy (CSCR) and pachychoroid-associated neovascularization. This study prospectively evaluates the efficacy and safety of faricimab compared to sham in CSCR with and without secondary neovascularization, using standardized anatomical and functional endpoints. The results of this trial may help define the role of dual pathway inhibition in CSCR and inform future treatment strategies for this challenging and vision threatening condition.

Participants needed: 50
Trial details
Phase: Phase 2Age: 21+Biological sex: AllType: InterventionalSponsor: Singapore National Eye CentreUpdated: Jul 2, 2026
Eligibility criteria

Age ≥21 years at the time of consent. [+8]

Presence of ocular inflammation or primary choroidal disorders. [+13]

Status: Not yet recruiting

Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients

By leveraging parameters including fractal dimension and topological index, we constructed a quantitative evaluation framework for ultra-widefield optical coherence tomography angiography (UWF-OCTA) images in patients with central serous chorioretinopathy (CSC), thus overcoming the limitations of conventional qualitative analysis.

Participants needed: 120
Trial details
Age: 18-60Biological sex: AllType: ObservationalSponsor: Sun Yat-sen UniversityUpdated: Jan 16, 2026Locations: 1
Eligibility criteria

Adults aged 18 to 60 years, inclusive; [+5]

Presence of systemic diseases that may affect study outcomes or participant safe... [+5]